Breast Cancer Liquid Biopsy Market Size & Growth Forecast 2027–2036, By Segments (Circulating Biomarkers, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Breast Cancer Liquid Biopsy Market size stood at USD 1.3 billion in 2026 and is predicted to grow at a 8.08% CAGR from 2027 to 2036, exceeding USD 2.83 billion by 2036. The industry revenue for 2027 is calculated at USD 1.39 billion.
Get more details on this report
Request Free Sample ReportBreast Cancer Liquid Biopsy Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for a 47.32% market share in 2026, supported by advanced oncology diagnostics, widespread molecular testing, and strong integration of liquid biopsy into clinical care pathways.
- Asia Pacific is expected to expand at a 9.61% CAGR, driven by broader access to oncology testing, growing adoption of minimally invasive diagnostics, and improving laboratory capabilities.
Segment Momentum
- Circulating Cell-free DNA (cfDNA) held a 56.28% share in 2026 because its minimally invasive approach supports repeated sampling, treatment monitoring, and efficient integration into routine clinical workflows.
- Early Detection/Screening is growing fastest as demand rises for less invasive testing that supports earlier clinical intervention, with repeatable and convenient liquid biopsy approaches expanding beyond treatment-stage decision-making.
Market Expansion Drivers
- Increasing breast cancer prevalence driving demand for rapid non-invasive diagnostic solutions.
- Growing transition from tissue biopsy to liquid biopsy improving cancer monitoring efficiency.
- Expanding precision oncology applications accelerating adoption of circulating tumor DNA testing technologies.
Leading Market Participants
- Leading players in the breast cancer liquid biopsy market include F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (United States), NeoGenomics, Inc. (United States), Sysmex Corporation (Japan), Myriad Genetics, Inc. (United States), Menarini Silicon Biosystems S.p.A. (Italy), Epic Sciences, Inc. (United States), Biocept, Inc. (United States), Guardant Health, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.3 billion
- 2027 Estimated Market Size: USD 1.39 billion.
- Projected Market Size: USD 2.83 billion by 2036
- Growth Forecast: 8.08% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Circulating Cell-free DNA (cfDNA) (Circulating Biomarkers) | Treatment Selection (Application)
- Emerging Opportunity Segment: Circulating Tumor Cells (CTCs) (Circulating Biomarkers) | Early Detection/Screening (Application)
Market Growth Drivers and Industry Trends
Increasing breast cancer prevalence driving demand for rapid non-invasive diagnostic solutions
The rising incidence of breast cancer is increasing the need for diagnostic approaches that can identify disease characteristics efficiently while minimizing the physical burden associated with conventional tissue sampling. This trend will drive the breast cancer liquid biopsy market growth as clinicians increasingly seek less invasive methods for detecting and monitoring tumor-related changes through blood-based analysis. Liquid biopsy can provide access to circulating biomarkers without requiring repeated surgical or needle-based tissue collection, which is particularly relevant when patients require ongoing assessment during treatment. The ability to obtain diagnostic information through a relatively simple blood sample can also support more frequent disease evaluation and help address situations where obtaining sufficient tumor tissue is difficult.
Growing transition from tissue biopsy to liquid biopsy improving cancer monitoring efficiency
The shift toward liquid biopsy is gaining momentum as healthcare providers look for more convenient approaches to repeated cancer monitoring and treatment assessment. The breast cancer liquid biopsy market is benefiting from this transition because blood-based testing can facilitate serial evaluation of tumor-derived biomarkers without repeatedly subjecting patients to invasive tissue collection. This approach can be especially useful when tumors are difficult to access or when disease characteristics change during the course of therapy. By enabling repeated sampling, liquid biopsy technologies can support closer monitoring of treatment response and disease progression while reducing some of the logistical and procedural challenges associated with conventional biopsy procedures.
Expanding precision oncology applications accelerating adoption of circulating tumor DNA testing technologies
The growing emphasis on individualized cancer treatment is creating additional opportunities for technologies capable of identifying molecular characteristics associated with a patient's disease. Within the breast cancer liquid biopsy market, circulating tumor DNA testing can support precision oncology by providing molecular information that may help clinicians understand tumor evolution and identify relevant genomic alterations. Analysis of tumor-derived DNA circulating in the bloodstream can complement conventional diagnostic information and provide a means of tracking molecular changes during treatment. As oncology care increasingly focuses on selecting therapies according to specific tumor characteristics and monitoring changes over time, the clinical relevance of circulating tumor DNA analysis is expanding.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing breast cancer prevalence driving demand for rapid non-invasive diagnostic solutions | 1.90% | High | North America, Europe | High | Near Term |
| Growing transition from tissue biopsy to liquid biopsy improving cancer monitoring efficiency | 1.70% | Moderate | Asia Pacific, North America | High | Mid Term |
| Expanding precision oncology applications accelerating adoption of circulating tumor DNA testing technologies | 1.40% | High | Europe, North America | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the breast cancer liquid biopsy market, North America accounted for the largest share of 47.32% in 2026, supported by advanced cancer diagnostics infrastructure, strong adoption of precision medicine, and substantial clinical interest in minimally invasive testing approaches. The region benefits from established healthcare systems with greater access to molecular diagnostics and sophisticated oncology services. Increasing emphasis on early cancer detection, treatment monitoring, and personalized therapeutic decision-making is also strengthening demand for liquid biopsy technologies in breast cancer care.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing region, driven by expanding healthcare infrastructure, rising awareness of advanced cancer diagnostics, and increasing demand for less invasive approaches to disease detection and monitoring. Improvements in molecular testing capabilities and growing access to specialized oncology services are supporting broader adoption. The region’s large patient population, increasing healthcare investment, and growing focus on improving cancer diagnosis and treatment pathways are creating favorable conditions for liquid biopsy technologies.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Validation FocusGermany is strengthening breast cancer liquid biopsy adoption through evidence-based clinical implementation and advanced laboratory capabilities. German healthcare providers are emphasizing diagnostic accuracy, standardized workflows, and molecular testing integration within oncology practice.
France 🇫🇷
Oncology Diagnostic InnovationFrance is promoting breast cancer liquid biopsy through precision oncology initiatives and broader use of molecular diagnostics. Clinical centers in France are incorporating liquid biopsy into patient management strategies to support treatment selection and disease monitoring.
Italy 🇮🇹
Personalized Cancer MonitoringItaly is expanding breast cancer liquid biopsy applications within personalized oncology care and advanced diagnostic services. Hospitals and diagnostic laboratories in Italy are adopting molecular testing solutions that enhance treatment monitoring while reducing reliance on invasive procedures.
Japan 🇯🇵
Early Detection IntegrationJapan is incorporating breast cancer liquid biopsy technologies into precision medicine initiatives that support earlier disease assessment and treatment monitoring. Clinical institutions in Japan continue evaluating validated assays that complement conventional diagnostic approaches.
South Korea 🇰🇷
Molecular Testing ExpansionSouth Korea is advancing breast cancer liquid biopsy through investments in molecular diagnostics and precision oncology services. Healthcare organizations are integrating liquid biopsy platforms into cancer management workflows while expanding access to innovative diagnostic technologies.
United States 🇺🇸
Precision Diagnostics AdoptionThe U.S. is expanding breast cancer liquid biopsy adoption through precision oncology programs and advanced molecular testing capabilities. Healthcare providers are integrating minimally invasive diagnostics into treatment monitoring and personalized care pathways supported by ongoing clinical validation.
Segment Leadership and Growth Trends
Breast Cancer Liquid Biopsy Market Share (%), by Circulating Biomarkers, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportCirculating Biomarkers Segment Analysis: Circulating Cell-free DNA (cfDNA) (Largest Segment) vs Circulating Tumor Cells (CTCs) (Fastest-Growing Segment)
Circulating cell-free DNA (cfDNA) accounted for the largest share of the breast cancer liquid biopsy market at 56.28% in 2026, supported by its increasing relevance in minimally invasive cancer assessment and molecular profiling. Analysis of cfDNA can provide clinically useful information from a blood sample while reducing reliance on repeated tissue-based procedures. Growing adoption of precision oncology and interest in monitoring molecular changes during treatment are strengthening demand for liquid-biopsy approaches based on circulating genetic material.
Circulating tumor cells (CTCs) are gaining traction as advances in liquid-biopsy technologies improve the ability to identify and characterize tumor-derived cells in blood samples. CTC analysis can provide insights into tumor behavior and disease progression, supporting applications in cancer monitoring and personalized treatment strategies. Increasing research emphasis on minimally invasive biomarkers and the broader shift toward individualized cancer management are creating stronger opportunities for CTC-based approaches.
Application Segment Analysis: Treatment Selection (Largest Segment) vs Early Detection/Screening (Fastest-Growing Segment)
Treatment selection represented the largest application segment of the breast cancer liquid biopsy market, with a 54.08% share in 2026. Its leading position is supported by the growing importance of molecular information in guiding individualized treatment decisions. Liquid biopsy can provide actionable insights into tumor characteristics without requiring repeated invasive tissue sampling, making it valuable for evaluating treatment-relevant biomarkers and monitoring disease changes. The increasing adoption of precision medicine is therefore reinforcing demand for liquid-biopsy applications in therapeutic decision-making.
Early detection/screening is advancing rapidly as healthcare systems and researchers place greater emphasis on identifying breast cancer at earlier stages through minimally invasive approaches. Liquid biopsy technologies offer the potential to complement conventional diagnostic pathways by detecting molecular signals associated with disease. Continued development of sensitive biomarker analysis and rising interest in less invasive screening strategies are supporting the expansion of this application area.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Circulating Biomarkers | Circulating Tumor Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), Others | Circulating Cell-free DNA (cfDNA) | Circulating Tumor Cells (CTCs) |
| Application | Early Detection/Screening, Diagnosis, Treatment Selection, Monitoring | Treatment Selection | Early Detection/Screening |
Competitive Landscape and Market Positioning
Key companies in the breast cancer liquid biopsy market:
1. F. Hoffmann-La Roche Ltd. (Switzerland)
2. QIAGEN N.V. (Netherlands)
3. Thermo Fisher Scientific Inc. (United States)
4. NeoGenomics Inc. (United States)
5. Sysmex Corporation (Japan)
6. Myriad Genetics Inc. (United States)
7. Menarini Silicon Biosystems S.p.A. (Italy)
8. Epic Sciences Inc. (United States)
9. Biocept Inc. (United States)
10. Guardant Health Inc. (United States)
Technological progress in molecular diagnostics is significantly influencing the breast cancer liquid biopsy market. Industry players are concentrating on improving assay sensitivity, biomarker detection accuracy, and non-invasive testing capabilities to support earlier cancer detection and treatment monitoring. Ongoing research initiatives focused on expanding clinical applications and integrating genomic profiling tools are also strengthening the competitive environment and driving broader adoption of precision oncology solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| NeoGenomics Inc. (United States) | |||||||
| Sysmex Corporation (Japan) | |||||||
| Myriad Genetics Inc. (United States) | |||||||
| Menarini Silicon Biosystems S.p.A. (Italy) | |||||||
| Epic Sciences Inc. (United States) | |||||||
| Biocept Inc. (United States) | |||||||
| Guardant Health Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Illumina Inc. | Aug-24 | Illumina expanded its oncology portfolio by introducing high-throughput sequencing compatibility for the TruSight Oncology 500 ctDNA v2 assay. This update enhances the scalability of noninvasive genomic profiling, providing researchers with a more efficient tool for detecting circulating tumor DNA (ctDNA) variants essential for breast cancer research and therapeutic monitoring. |
| Twist Bioscience | Feb-24 | Twist Bioscience launched a specialized cfDNA library preparation kit designed to optimize liquid biopsy workflows. The kit improves the sensitivity and accuracy of variant detection from degraded or low-input cell-free DNA samples, facilitating more robust analytical performance for researchers developing diagnostic assays for early cancer detection and minimal residual disease monitoring. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Breast Cancer Liquid Biopsy Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Clinical Setting | Hospitals & Academic Medical Centers, Specialty Cancer Centers, Diagnostic Laboratories, Physician Offices & Clinics |
| Sample Type | Blood/Plasma, Serum, Urine, Other Biological Samples |
| Testing Workflow | Laboratory-Developed Testing, Centralized Laboratory Testing, Decentralized/Point-of-Care Testing |
Breast Cancer Liquid Biopsy Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Adoption Roadmap Analysis |
|
| Companion Diagnostics Opportunity Assessment |
|
| Patient Access & Testing Ecosystem Analysis |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the breast cancer liquid biopsy market?
What are the growth projections for the breast cancer liquid biopsy industry?
How is the shift toward non-invasive diagnostic pathways changing clinical demand in the breast cancer liquid biopsy market?
Why is circulating tumor DNA testing becoming central to precision oncology applications in breast cancer management?
Why does Circulating Cell-free DNA (cfDNA) lead the breast cancer liquid biopsy market?
Why is Early Detection/Screening the fastest-growing application in the breast cancer liquid biopsy market?
Why does North America dominate the breast cancer liquid biopsy market?
What is driving growth in the breast cancer liquid biopsy market across Asia Pacific?
Who are the leading players in the breast cancer liquid biopsy landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization